bluuebunny/crossref_metadata_2025_split huggingface dataset:
Craniofacial phenotypes associated with Robinow syndrome
Authors: Conlon Christopher J. , Abu‐Ghname Amjed , Raghuram Anjali C. , Davis Matthew J. , Guillen Diana E. , Sutton V. Reid , Carvalho Claudia M. B. , Maricevich Renata S. 
Published: November 2020

AbstractRobinow syndrome is characterized by mesomelic limb shortening, hemivertebrae, and genital hypoplasia. Due to low prevalence and considerable phenotypic variability, it has been challenging to definitively characterize features of Robinow syndrome. While craniofacial abnormalities associated with Robinow syndrome have been broadly described, there is a lack of detailed descriptions of genotype‐specific phenotypic craniofacial features. Patients with Robinow syndrome were invited for a multidisciplinary evaluation conducted by specialist physicians at our institution. A focused assessment of the craniofacial manifestations was performed by a single expert examiner using clinical examination and standard photographic images. A total of 13 patients with clinical and molecular diagnoses consistent with either dominant Robinow syndrome (DRS) or recessive Robinow syndrome (RRS) were evaluated. On craniofacial examination, gingival hyperplasia was nearly ubiquitous in all patients. Orbital hypertelorism, a short nose with anteverted and flared nares, a triangular mouth with a long philtrum, cleft palate, macrocephaly, and frontal bossing were not observed in all individuals but affected individuals with both DRS and RRS. Other anomalies were more selective in their distribution in this patient cohort. We present a comprehensive analysis of the craniofacial findings in patients with Robinow Syndrome, describing associated morphological features and correlating phenotypic manifestations to underlying genotype in a manner relevant for early recognition and focused evaluation of these patients.
Chiral Bifunctional Sulfide‐Catalyzed Highly Enantioselective Bromolactonizations of 4‐Pentenoic Acids
Authors: Nishiyori Ryuichi , Okada Megumi , Maynard John R. J. , Shirakawa Seiji 
Published: November 2020

AbstractDespite extensive studies into the design of effective chiral catalysts for asymmetric halolactonizations, the development of highly enantioselective catalytic bromolactonization of 4‐aryl‐4‐pentenoic acids, which is one of the benchmark reactions, has not been completely satisfactory. Herein, we report the use of BINOL‐derived chiral bifunctional sulfide catalysts to achieve highly enantioselective bromolactonizations of 4‐aryl‐4‐pentenoic acids. The importance of the bifunctional design of chiral sulfide catalysts was clearly demonstrated in the present study. Furthermore, the present catalytic asymmetric reaction system could be applied to highly stereoselective desymmetrizing bromolactonizations.
Additive manufacturing of green composites: Poly (lactic acid) reinforced with keratin materials obtained from Angora rabbit hair
Authors: Flores‐Hernandez Cynthia Graciela , Velasco‐Santos Carlos , Rivera‐Armenta José Luis , Gomez‐Guzman Oscar , Yañez‐Limon José Martin , Olivas‐Armendariz Imelda , Lopez‐Barroso Juventino , Martinez‐Hernandez Ana Laura 
Published: November 2020

AbstractIn this research, additive manufacturing of polylactic acid (PLA) reinforced with keratin was studied. Keratin was obtained from Angora rabbit hair and modified with NaOH. Scanning electron microscopy (SEM) images showed that the modified surfaces were rougher than untreated surfaces. Furthermore, SEM images in the composites' fracture regions showed surface changes, associated with the nature of the reinforcement. Likewise, thermomechanical properties of the composites were attributed to the nature of the reinforcement and the type of keratin. Besides, the 3D printed composites showed higher thermal conductivity values than PLA with the addition of keratin. Cytotoxicity tests revealed an improvement in cell growth compared to the control and PLA. These results are meaningful toward the development of high thermal conductors and biocompatible composites with applications in different fields, where the use of only natural polymers is necessary.
Berberine promotes peri‐implant osteogenesis in diabetic rats by ROS‐mediated IRS‐1 pathway
Authors: Shao Jingjing , Liu Shibo , Zheng Xiao , Chen Jing , Li Lei , Zhu Zhimin 
Published: November 2020

AbstractAccompanying with diabetes mellitus‐induced osteoporosis (DM‐OS), diabetic patients show poor peri‐implant osteogenesis after implantation for dentition defect. Berberine (BBR), a candidate oral hypoglycemic agent, is a promising agent for treating DM‐OS. In this study, BBR was applied on DM rats and high‐glucose‐cultured bone mesenchymal stem cells (BMSCs) to investigate its therapeutic mechanism on DM‐OS, thus laying a theoretical basis for the future application of BBR in implant restoration. Phenotypes were assessed in the DM rats after 4 w of gavage with BBR. Furthermore, BMSCs were cultured with high glucose and BBR. Cell Counting Kit‐8, 2′,7′‐dichlorofluorescin diacetate (H2DCF‐DA), quantitative real‐time PCR (qRT‐PCR), and western blot were performed to estimate the cell proliferation, oxidative stress, and osteogenic differentiation. Moreover, the DM rats treated with BBR and insulin receptor substrate‐1 anti‐sense oligonucleotide (IRS‐1‐ASO) underwent a 4‐w implant‐healing period and then micro computed tomography (Micro‐CT) and histology were performed to verify the mechanism. Results showed that the 4‐w administration of BBR markedly improved the glucose metabolism and bone metabolism in the DM rats. in vitro experiments revealed that BBR alleviated high‐glucose‐inhibited osteogenesis of the BMSCs by upregulating reactive oxygen species (ROS)‐mediated IRS‐1 signaling. Besides, injection of IRS‐1‐ASO abolished the BBR promotion of implant osseointegration in the DM rats. In conclusion, targeting ROS‐mediated IRS‐1 signaling, BBR acted as an efficient agent to advance osseointegration in DM, which indicated that BBR use is a good strategy for future implants restoration in diabetic patients.
Construction of a disease‐specific lncRNA‐miRNA‐mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma
Authors: Zhang Qi , Sun Lin , Zhang Qiuju , Zhang Wei , Tian Wei , Liu Meina , Wang Yupeng 
Published: November 2020

AbstractHepatocellular carcinoma (HCC) is a heterogeneous malignancy with a high incidence and poor prognosis. Exploration of the underlying mechanisms and effective prognostic indicators is conducive to clinical management and optimization of treatment. The RNA‐seq and clinical phenotype data of HCC were retrieved from The Cancer Genome Atlas (TCGA), and differential expression analysis was performed. Then, a differential lncRNA‐miRNA‐mRNA regulatory network was constructed, and the key genes were further identified and validated. By integrating this network with the online tool‐based ceRNA network, an HCC‐specific ceRNA network was obtained, and lncRNA‐miRNA‐mRNA regulatory axes were extracted. RNAs associated with prognosis were further obtained, and multivariate Cox regression models were established to identify the prognostic signature and nomogram. As a result, 198 DElncRNAs, 120 DEmiRNAs, and 2827 DEmRNAs were identified, and 30 key genes identified from the differential network were enriched in four cancer‐related pathways. Four HCC‐specific lncRNA‐miRNA‐mRNA regulatory axes were extracted, and SNHG11, CRNDE, MYLK‐AS1, E2F3, and CHEK1 were found to be related with HCC prognosis. Multivariate Cox regression analysis identified a prognostic signature, comprised of CRNDE, MYLK‐AS1, and CHEK1, for overall survival (OS) of HCC. A nomogram comprising the prognostic signature and pathological stage was established and showed some net clinical benefits. The AUC of the prognostic signature and nomogram for 1‐year, 3‐year, and 5‐year survival was 0.777 (0.657‐0.865), 0.722 (0.640‐0.848), and 0.630 (0.528‐0.823), and 0.751 (0.664‐0.870), 0.773 (0.707‐0.849), and 0.734 (0.638‐0.845), respectively. These results provided clues for the study of potential biomarkers and therapeutic targets for HCC. In addition, the obtained 30 key genes and 4 regulatory axes might also help elucidate the underlying mechanism of HCC.
Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma
Authors: Perret Audrey , Dômont Julien , Chamseddine Ali N. , Dumont Sarah N. , Verret Benjamin , Briand Sylvain , Court Charles , Lazure Thierry , Adam Julien , Ngo Carine , Even Caroline , Levy Antonin , Bayle Arnaud , Lucibello Francesca , Haddag‐Miliani Leila , Faron Matthieu , Honoré Charles , Le Cesne Axel , Mir Olivier 
Published: November 2020

AbstractTherapeutic options in patients with metastatic osteosarcoma are limited and effective systemic treatments are needed in this setting. The aim of this case series was to assess the efficacy and toxicity of oral metronomic etoposide in adult patients with progressive metastatic osteosarcoma. We retrospectively reviewed the electronic records of patients treated with oral metronomic etoposide (25 mg thrice daily, 3 weeks out of 4) from December 2002 to December 2018 at Gustave Roussy (Villejuif, France). The primary endpoint was progression‐free rate (PFR) at 4 months; secondary endpoints were: best response (according to RECIST v1.1), progression‐free survival (PFS), overall survival (OS) and safety. With a median follow‐up of 9.8 months, 37 patients were eligible for this analysis: 68% males, median age 42 (range: 21–75), 19% with synchronous metastases, 92% with lung metastases, median PS: 1 (range: 0–3). Median number of previous treatment lines in the metastatic setting was 1 (range: 0–4). Progression‐free rate at 4 months was 40.3% (95% CI: 24.5–56.2). Best response was partial response in 11% and stable disease in 35% of patients (disease control rate: 46%). Median PFS was 3.1 months (95% CI: 2.5–4.7) and median OS was 9.8 months (95% CI: 5.1–12.3). Toxicity profile was acceptable, with 13% grade 3 haematological toxicities (anaemia and neutropenia), without any grade 3–4 non‐haematological toxicity. In our experience, oral metronomic etoposide demonstrated effective palliation along with acceptable toxicity in patients with progressive metastatic osteosarcoma.
New Pyrano‐4H‐benzo[g]chromene‐5,10‐diones with Antiparasitic and Antioxidant Activities
Authors: Al Nasr Ibrahim S. , Jentzsch Jana , Shaikh Amin , Singh Shuveksh Priti , Koko Waleed S. , Khan Tariq A. , Ahmed Khursheed , Schobert Rainer , Ersfeld Klaus , Biersack Bernhard 
Published: November 2020

AbstractNew pyranonaphthoquinone derivatives were synthesized and investigated for their activity against Trypanosoma brucei, Leishmania major, and Toxoplasma gondii parasites. The pentafluorophenyl derivative was efficacious against T. brucei with single digit micromolar EC50 values and against T. gondii with even sub‐micromolar values. The 3‐chloro‐4,5‐dimethoxyphenyl derivative showed an activity against amastigotes of Leishmania major parasites comparable to that of amphotericin B. In addition, antioxidant activities were observed for the bromophenyl derivatives, and their redox behavior was studied by cyclovoltammetry. Anti‐parasitic and antioxidative activities of the new naphthoquinone derivatives appear uncorrelated.
Synthetic Application of Cyclodextrins in Combination with Metal Ions, Complexes, and Metal Particles
Authors: Molnár Árpád 
Published: November 2020

AbstractCyclodextrins are green, environmentally benign products available through the enzymatic degradation of starch for a multitude of varied applications. This review attempts to collect useful information with respect to catalytic studies performed with the use of cyclodextrin and modified cyclodextrin preparations applied in combination of or loaded with varied catalytically active species including metal ions, complexes, and metal particles. Major sections are about their use in hydrogenation, reduction, oxidation, hydroformylation and coupling reactions. Additional sections include their utilization in ring formation and ring opening as well as degradation of pollutants. In the last part, examples about ester hydrolysis, hydroboration and hydrosilylation, as well as hydrogen production are treated. Data collected and analyzed indicate the importance and high potential of cyclodextrin‐based catalysts in sustainable chemistry.
Bifunctional α‐MnO2 and Co3O4 Catalyst for Oxygen Electrocatalysis in Alkaline Solution
Authors: Fink Michael F. , Eckhardt Julia , Khadke Prashant , Gerdes Thorsten , Roth Christina 
Published: November 2020

AbstractLow cost and abundant catalysts demonstrating high activity and stability towards the oxygen reactions, i. e., the oxygen reduction (ORR) and oxygen evolution reaction (OER), are crucial for the development of electrically rechargeable zinc‐air batteries. Herein, the facile synthesis and systematic characterisation of two highly active and stable oxygen electrocatalysts, i. e., high surface area α‐MnO2 microspheres and nanoparticulate Co3O4, are reported. α‐MnO2 exhibits low half‐wave potential and potential of −0.197 and −0.226 V (vs. Ag/AgCl) at −3 mA cm−2, respectively, that are only marginally higher compared to commercial Pt/C (E1/2=−0.161 V, Ej=‐3=−0.171 V) for ORR. Meanwhile, Co3O4 needs a potential of 0.601 V (vs. Ag/AgCl) to drive 10 mA cm−2 being competitive to commercial Ir/C (Ej=10=0.60 V) for OER. In order to create a bifunctional catalyst, two approaches were pursued: i) Co3O4 nanoparticles were homogeneously grown on the surface of α‐MnO2 microspheres yielding a radial hybrid composite catalyst material in the form of a core (α‐MnO2) shell (Co3O4) structure and ii), much simpler, individual α‐MnO2 microspheres and Co3O4 nanoparticles were physically mixed in a powder blend. The powder blend demonstrates superior overall bifunctional catalytic properties such that the individual catalysts still dominate their respective oxygen reaction and, due to synergistic interactions between both catalysts, an improved ORR activity could be achieved.
A randomized, open‐label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft‐tissue sarcoma
Authors: Somaiah Neeta , Van Tine Brian Andrew , Wahlquist Amy E. , Milhem Mohammed M. , Hill Elizabeth G. , Garrett‐Mayer Elizabeth , Armeson Kent E. , Schuetze Scott M. , Meyer Christian F. , Reuben Daniel Y. , Elias Anthony D. , Read William L. , Chawla Sant P. , Kraft Andrew S. 
Published: November 2020

BackgroundTherapeutic options for patients with advanced soft‐tissue sarcoma (STS) are limited. The goal of the current phase 2 study was to examine the clinical activity and safety of the combination of gemcitabine plus pazopanib, a multityrosine kinase inhibitor with activity in STS.MethodsThe current randomized, phase 2 trial enrolled patients with advanced nonadipocytic STS who had received prior anthracycline‐based therapy. Patients were assigned 1:1 to receive gemcitabine at a dose of 1000 mg/m2 on days 1 and 8 with pazopanib at a dose of 800 mg daily (G+P) or gemcitabine at a dose of 900 mg/m2 on days 1 and 8 and docetaxel at a dose of 100 mg/m2 on day 8 (G+T) every 3 weeks. Crossover was allowed at the time of disease progression. The study used a noncomparative statistical design based on the precision of 95% confidence intervals for reporting the primary endpoints of median progression‐free survival (PFS) and rate of grade ≥3 adverse events (AEs) for these 2 regimens based on the intent‐to‐treat patient population (AEs were graded using version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events).ResultsA total of 90 patients were enrolled: 45 patients on each treatment arm. The median PFS was 4.1 months for each arm (P = .3, log‐rank test). The best overall response of stable disease or better (complete response + partial response + stable disease) was the same for both treatment arms (64% for both the G+T and G+P arms). The rate of related grade ≥3 AEs was 82% for the G+T arm and 78% for the G+P arm. Related grade ≥3 AEs occurring in ≥10% of patients in the G+T and G+P arms were anemia (36% and 20%, respectively), fatigue (29% and 13%, respectively), thrombocytopenia (53% and 49%, respectively), neutropenia (20% and 49%, respectively), lymphopenia (13% and 11%, respectively), and hypertension (2% and 20%, respectively).ConclusionsThe data from the current study have demonstrated the safety and efficacy of G+P as an alternative to G+T for patients with nonadipocytic STS.
Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative‐intent chemotherapy: A Wisconsin Oncology Network study
Authors: Tevaarwerk Amye J. , Kwekkeboom Kris , Buhr Kevin A. , Dennee Alexandra , Conkright William , Onitilo Adedayo A. , Robinson Emily , Ahuja Harish , Kwong Roger W. , Nanad Ranveer , Wiegmann Douglas A. , Chen Karen , LoConte Noelle K. , Wisinski Kari B. , Sesto Mary E. 
Published: November 2020

BackgroundPostcancer work limitations may affect a substantial proportion of patients and contribute to the “financial toxicity” of cancer treatment. The degree and nature of work limitations and employment outcomes are poorly understood for cancer patients, particularly in the immediate period of transition after active treatment. We prospectively examined employment, work ability, and work limitations during and after treatment.MethodsA total of 120 patients receiving curative therapy who were employed prior to their cancer diagnosis and who intended to work during or after end of treatment (EOT) completed surveys at baseline (pretreatment), EOT, and 3, 6, and 12 months after EOT. Surveys included measures of employment, work ability, and work limitations. Descriptive statistics (frequencies, percentages, means with standard deviations) were calculated.ResultsA total of 111 participants completed the baseline survey. On average, participants were 48 years of age and were mostly white (95%) and female (82%) with a diagnosis of breast cancer (69%). Full‐time employment decreased during therapy (from 88% to 50%) and returned to near prediagnosis levels by 12‐month follow‐up (78%). Work‐related productivity loss due to health was high during treatment.ConclusionsThis study is the first to report the effects of curative intent cancer therapy on employment, work ability, and work limitations both during and after treatment. Perceived work ability was generally high overall 12 months after EOT, although a minority reported persistent difficulty. A prospective analysis of factors (eg, job type, education, symptoms) most associated with work limitations is underway to assist in identifying at‐risk patients.
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
Authors: Stock Wendy , Martinelli Giovanni , Stelljes Matthias , DeAngelo Daniel J. , Gökbuget Nicola , Advani Anjali S. , O’Brien Susan , Liedtke Michaela , Merchant Akil A. , Cassaday Ryan D. , Wang Tao , Zhang Hui , Vandendries Erik , Jabbour Elias , Marks David I. , Kantarjian Hagop M. 
Published: November 2020

BackgroundPatients with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options.MethodsThe efficacy of inotuzumab ozogamicin (InO), a humanized anti‐CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, was evaluated in R/R ALL patients in the phase 1/2 study 1010 (NCT01363297) and open‐label, randomized, phase 3 study 1022 (INO‐VATE; NCT01564784). This analysis focused specifically on Ph+ R/R ALL patients. In study 1022, Ph+ patients were randomly assigned 1:1 to InO (n = 22) or standard intensive chemotherapy (SC) (n = 27) and 16 Ph+ patients in study 1010 received InO.ResultsIn study 1022, rates of complete remission/complete remission with incomplete hematologic recovery (CR/CRi) and minimal residual disease (MRD) negativity (patients achieving CR/CRi) were higher with InO (CR/CRi = 73%; MRD = 81%) versus SC (CR/CRi = 56%; MRD = 33%). The corresponding rates in study 1010 were 56% (CR/CRi) and 100% (MRD). The hematopoietic stem cell transplantation (HSCT) rate in study 1022 was 41% versus 19% for InO versus SC; however, there was no benefit in overall survival (median OS: 8.7 vs 8.4 months; hazard ratio, 1.17 [95% CI, 0.64‐2.14]). The probability of being event‐free (progression‐free survival) at 12 months was greater with InO versus SC (20.1% vs 4.8%).ConclusionGiven the substantial improvement in responses and rates of HSCT, InO is an important treatment option for patients with R/R Ph+ ALL. Future studies need to consider better characterization of disease characteristics, more sensitive MRD measurements, MRD‐directed therapy before HSCT, and potentially combination therapies, including tyrosine kinase inhibitors.
Health‐related quality of life outcomes among breast cancer survivors
Authors: Park Jihye , Rodriguez Juan L. , O’Brien Katie M. , Nichols Hazel B. , Hodgson M. Elizabeth , Weinberg Clarice R. , Sandler Dale P. 
Published: November 2020

BackgroundData from a nationwide sample of US breast cancer survivors were used to examine associations between patient characteristics (breast cancer clinical features, prognostic factors, and treatments) and health‐related quality of life (HRQOL). Associations between postdiagnosis HRQOL and mortality were then evaluated.MethodsThe authors identified female breast cancer survivors (n = 2453) from the Sister Study or Two Sister Study who were at least 1 year from breast cancer diagnosis and who had responded to a survivorship survey in 2012. HRQOL was assessed with the Patient‐Reported Outcomes Measurement Information System (PROMIS) Global 10 measures. Multivariable linear regression was used to assess predictors associated with HRQOL. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between HRQOL and all‐cause mortality.ResultsHRQOL, assessed an average of 4.9 years after the cancer diagnosis (standard deviation of 1.9 years), was negatively associated with a higher cancer stage at diagnosis; a higher comorbidity score at the survey; experience of surgical complications; dissatisfaction with breast surgery; and experience of any recent recurrence, metastasis, or secondary malignancy. Since the completion of the survey, there were 85 deaths (3.5%) during a mean follow‐up of 4 years (standard deviation of 0.5 years). In multivariate models, decreases in PROMIS physical T scores and mental T scores were associated with increased mortality (HR for physical T scores, 1.08; 95% CI, 1.05‐1.11; HR for mental T scores, 1.03; 95% CI, 1.01‐1.06).ConclusionsPrognostic and cancer treatment–related factors affect HRQOL in breast cancer survivors and may inform targeted survivorship care. PROMIS global health measures may offer additional insights into patients' well‐being and mortality risk.Lay Summary

Findings from a study suggest that prognostic and cancer treatment–related factors affect health‐related quality of life (HRQOL) in breast cancer survivors and that poor HRQOL may increase the mortality risk.

The evaluation of HRQOL is important because it may hold potential as a tool for optimizing survivorship care.